無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のバイオシミュレーション市場予測 (2017〜2027年):製品別 (PK/PD、分子、毒性、PBPK、治験デザイン)、サービス別、用途別 (薬剤開発、前臨床検査、ADME/毒性、治験、創薬)、エンドユーザー別、地域収益見通し

Biosimulation World Market 2017-2027: Revenue Prospects By Product (PK/PD, Molecular, Toxicity, PBPK, Trial Design), Services, Application (Drug Development, Preclinical Testing, ADME/Tox, PK/PD, Clinical Trials, Drug Discovery), End User and Geography

発行 Visiongain Ltd 商品コード 534098
出版日 ページ情報 英文 148 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=148.62円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
世界のバイオシミュレーション市場予測 (2017〜2027年):製品別 (PK/PD、分子、毒性、PBPK、治験デザイン)、サービス別、用途別 (薬剤開発、前臨床検査、ADME/毒性、治験、創薬)、エンドユーザー別、地域収益見通し Biosimulation World Market 2017-2027: Revenue Prospects By Product (PK/PD, Molecular, Toxicity, PBPK, Trial Design), Services, Application (Drug Development, Preclinical Testing, ADME/Tox, PK/PD, Clinical Trials, Drug Discovery), End User and Geography
出版日: 2017年06月19日 ページ情報: 英文 148 Pages
概要

世界のバイオシミュレーション市場は2017年に12億米ドルを超えました。同市場は2027年にかけ大きく収益を上げるものと予測されています。

当レポートでは、世界のバイオシミュレーション市場について調査し、市場の概要と製品別、サービス別、用途別、エンドユーザー別、地域別動向、および市場に参入する主要企業のプロファイルなどをまとめています。

第1章 調査の概要

第2章 バイオシミュレーションのイントロダクション

第3章 製品別市場

  • 予測と分析
  • PK/PDモデリングおよびシミュレーションソフトウェア
    • 分子モデリングとシミュレーションソフトウェア
    • 毒性予測ソフトウェア
    • PBPKモデリングとシミュレーションソフトウェア
    • 治験デザインソフトウェア
    • その他
  • バイオシミュレーションサービス
    • 社内サービス
    • 外部/受託サービス

第4章 用途別市場

  • 薬剤開発
  • 創薬
  • その他

第5章 エンドユーザー別市場

  • 製薬会社およびバイオテクノロジー企業
  • 医薬品研究開発受託機関
  • 学術・政府研究機関
  • 法規制当局
  • その他

第6章 地域別市場予測

  • 地域別内訳
  • 北米
  • 欧州
  • ラテンアメリカ
  • その他

第7章 定性的分析

  • SWOT分析
  • 強み
  • 弱み
  • ポーターズファイブフォース分析
  • 促進因子
  • 阻害因子

第8章 主要企業

  • Accelrys Inc
  • Certara
  • Simulation Plus Inc.
  • Dassault Systems SA
  • Schrodinger INC.
  • Advanced Chemistry Development, INC
  • Chemical Computing Group
  • Entelos Holding Corporation
  • Genedata AG
  • Physiomics PLC

第9章 結論

第10章 用語

目次
Product Code: PHA0203

Title:
Biosimulation World Market 2017-2027
Revenue Prospects by Product (PK/PD, Molecular, Toxicity, PBPK, Trial Design), Services (In-House, External), Application (Drug Development, Preclinical Testing, ADME/Tox, PK/PD, Clinical Trials, Drug Discovery, End User (Pharmaceutical and Biotechnology Companies, CROs, Academic & Government, Regulatory Authorities) and Geography.

Biosimulation - our new study reveals trends, R&D progress, and predicted revenues

Where is the Biosimulation market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead

Our 148-page report provides 112 tables, charts, and graphs, providing over 1700 unique datapoints. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Biosimulation market. See how to exploit the opportunities.

Forecasts to 2027 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market, there are forecasts for 2 Service Types, 5 Biosimulation software products, 6 software applications and 4 biosimulation end-users

Biosimulation Software, by Product

  • PK/PD
  • Molecular
  • Toxicity
  • PBPK
  • Trial Design

Biosimulation Services

  • In-House
  • External / Contract

Biosimulation, by Application

  • Drug Development
  • Preclinical Testing
  • ADME/Tox
  • PK/PD
  • Clinical Trials
  • Drug Discovery

Biosimulation, by End User

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organisations (CROs)
  • Academic & Government
  • Regulatory Authorities

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 11 leading national markets:

  • North America:
    • The US
    • Canada
    • Mexico
  • Europe:
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • RoE
  • APAC:
    • Japan
    • China
    • India
    • RoA
    • RoW

The report also includes profiles and forecasts for some of the leading companies in the Biosimulation market, with a focus on the Biosimulation segment of these companies' operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, Germany, France and China in particular, will continue to achieve high revenue growth to 2027.

Leading companies and the potential for market growth

Overall world revenue for Biosimulation will surpass $1.2bn in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing cost of drug development and increasing need for simulation software to reduce

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Biosimulation Market report helps you

In summary, our 125-page report provides you with the following knowledge:

  • Revenue forecasts to 2027 for the Biosimulation market and 3 different segmentations, with forecasts for 2 Services, 5 Products, 6 Applications and 4 End Users - discover the industry's prospects, finding the most lucrative places for investments and revenues
  • Revenue forecasts to 2027 for 11 of the leading national markets - US, Canada, Mexico, Germany, France, Italy, Spain, Russia, Japan, China, India,
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market - including company profiles and forecasts for 10 companies' biosimulation segment revenues to 2027
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the Biosimulation market and leading companies. You will find data, trends and predictions.

Get our report today Biosimulation World Market 2017-2027: Revenue Prospects by Product (PK/PD, Molecular, Toxicity, PBPK, Trial Design), Services (In-House, External), Application (Drug Development, Preclinical Testing, ADME/Tox, PK/PD, Clinical Trials, Drug Discovery, End User (Pharmaceutical and Biotechnology Companies, CROs, Academic & Government, Regulatory Authorities) and Geography. Avoid missing out - get our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Biosimulation Market Overview
  • 1.2. Why You Should Read This Report
  • 1.3. Key Questions Answered by This Analytical Report
  • 1.4. Who is This Report For?
  • 1.5. Methodology
  • 1.6. Frequently Asked Questions (FAQ)
  • 1.7. Associated Visiongain Reports
  • 1.8. About Visiongain

2. Introduction to Biosimulation

  • 2.1. What is Biosimulation?
  • 2.2. Classification of Biosimulation

3. Biosimulation: World Market by Product 2017-2027

  • 3.1. Biosimulation Software Submarket Forecast & Analysis 2017-2027
  • 3.2. PK/PD Modelling and Simulation Software
    • 3.2.1. Molecular Modelling and Simulation Software
    • 3.2.2. Toxicity Prediction Software
    • 3.2.3. PBPK Modelling and Simulation Software
    • 3.2.4. Trial Design Software
    • 3.2.5. Other Software
  • 3.3. Biosimulation Services Submarket Forecast & Analysis 2017-2027
    • 3.3.1. In-House Services
    • 3.3.2. External/Contract Services

4. Biosimulation: World Market by Application 2017-2027

  • 4.1. Drug Development Submarket Forecast & Analysis 2017-2027
    • 4.1.1. Preclinical Testing Submarket Forecast & Analysis 2017-2027
      • 4.1.1.1. ADME/Tox Submarket Forecast & Analysis 2017-2027
      • 4.1.1.2. PK/PD Submarket Forecast & Analysis 2017-2027
    • 4.1.2. Clinical Trials Submarket Forecast & Analysis 2017-2027
  • 4.2. Drug Discovery Submarket Forecast & Analysis 2017-2027
    • 4.2.1. Target Identification and Validation Submarket Forecast & Analysis 2017-2027
    • 4.2.2. Lead Identification and Optimization Submarket Forecast & Analysis 2017-2027
  • 4.3. Other Applications Submarket Forecast & Analysis 2017-2027

5. Biosimulation: World Market by End Users 2017-2027

  • 5.1. Pharmaceutical and Biotechnology Companies
  • 5.2. Contract Research Organizations
  • 5.3. Academic and Government Research Institutes
  • 5.4. Regulatory Authorities
  • 5.5. Others

6. Regional Biosimulation Market Forecasts 2017-2027

  • 6.1. Regional Biosimulation Market Forecasts 2017-2027
  • 6.2. North American Biosimulation Market Forecasts 2017-2027
    • 6.2.1. USA Biosimulation Market Forecasts 2017-2027
    • 6.2.2. Canada Biosimulation Market Forecasts 2017-2027
    • 6.2.3. Mexico Biosimulation Market Forecasts 2017-2027
  • 6.3. European Biosimulation Market Forecasts 2017-2027
    • 6.3.1. Germany Biosimulation Market Forecasts 2017-2027
    • 6.3.2. France Biosimulation Market Forecasts 2017-2027
    • 6.3.3. Italy Biosimulation Market Forecasts 2017-2027
    • 6.3.4. Spain Biosimulation Market Forecasts 2017-2027
    • 6.3.5. Russia Biosimulation Market Forecasts 2017-2027
    • 6.3.6. Rest of Europe Biosimulation Market Forecasts 2017-2027
  • 6.4. Asia-Pacific Biosimulation Market Forecasts 2017-2027
    • 6.4.1. China Biosimulation Market Forecasts 2017-2027
    • 6.4.2. India Biosimulation Market Forecasts 2017-2027
    • 6.4.3. Japan Biosimulation Market Forecasts 2017-2027
    • 6.4.4. Rest of Asia-Pacific Biosimulation Market Forecasts 2017-2027
  • 6.5. RoW Biosimulation Market Forecasts 2017-2027

7. Qualitative Analysis of Biosimulation Market

  • 7.1. SWOT Analysis
  • 7.2. Strengths
    • 7.2.1. Reduction in Drug Discovery and Development Costs
    • 7.2.2. Introduction of New Products
    • 7.2.3. Opportunities
    • 7.2.4. Increased Demand from the Pharmaceutical Industry
    • 7.2.5. Increased Need for Ethical Practices in R&D
  • 7.3. Weaknesses
    • 7.3.1. Issues with Prediction Accuracy
    • 7.3.2. Lack of Sufficient Technical Expertise and Supporting Infrastructure
    • 7.3.3. Threats
    • 7.3.4. High R&D Costs
    • 7.3.5. Undefined Regulations
  • 7.4. Porter's Five Forces Analysis of the Biosimulation Market
    • 7.4.1. Rivalry among Competitors [High]
    • 7.4.2. Threat of New Entrants [Medium]
    • 7.4.3. Power of Suppliers [Low]
    • 7.4.4. Power of Buyers [Medium]
    • 7.4.5. Threat of Substitutes [Medium]
  • 7.5. Drivers
    • 7.5.1. Increasing investment in the R&D sector of the pharmaceutical and biotechnology industries
    • 7.5.2. Increase in the technological advancements
    • 7.5.3. Boost in the growth of pharmaceutical and biotechnology industries
    • 7.5.4. Increase in the utilization of the personalized medicine coupled with growth in the biosimilars and biologics market
    • 7.5.5. Increasing need to reduce the drug discovery and development cost
  • 7.6. Restraints
    • 7.6.1. Dearth of skilled workforce
    • 7.6.2. Lack of standardization-A major hurdle for the biosimulation market growth

8. Leading Companies in The Biosimulation Market

  • 8.1. Accelrys Inc
    • 8.1.1. Accelrys Product Portfolio
    • 8.1.2. Accelrys Sales Analysis
    • 8.1.3. Key developments of Accelrys
  • 8.2. Certara
    • 8.2.1. Certara Product Portfolio
    • 8.2.2. Certara Sales Analysis
    • 8.2.3. Key developments of Certara
  • 8.3. Simulation Plus Inc.
    • 8.3.1. Simulation Plus Product Portfolio
    • 8.3.2. Simulation Plus Sales Analysis
    • 8.3.3. Key developments of Simulation Plus
  • 8.4. Dassault Systems SA
    • 8.4.1. Dassualt Systemes Product Portfolio
    • 8.4.2. Dassualt SystemsSales Analysis
    • 8.4.3. Key developments of Dassault Systems
  • 8.5. Schrödinger INC.
    • 8.5.1. Schrödinger Product Portfolio
    • 8.5.2. Schrödinger Sales Analysis
    • 8.5.3. Key developments of Schrödinger.
  • 8.6. Advanced Chemistry Development, INC
    • 8.6.1. Advanced Chemistry Development Product Portfolio
    • 8.6.2. Advanced Chemistry Development Inc. Sales Analysis
    • 8.6.3. Key developments of Advanced Chemistry Development
  • 8.7. Chemical Computing Group
    • 8.7.1. Chemical Computing Group Product Portfolio
    • 8.7.2. Chemical Computing Group Sales Analysis
    • 8.7.3. Key developments of Chemical Computing Group
  • 8.8. Entelos Holding Corporation
    • 8.8.1. Entelos Holding Corporation Product Portfolio
    • 8.8.2. Entelos Holding Corporation Sales Analysis
    • 8.8.3. Key developments of Entelos Holding Corporation
  • 8.9. Genedata AG
    • 8.9.1. Genedata AG Product Portfolio
    • 8.9.2. Genedata AG Sales Analysis
    • 8.9.3. Key developments of Genedata AG
  • 8.10. Physiomics PLC
    • 8.10.1. Physiomics Product Portfolio
    • 8.10.2. Physiomics Sales Analysis
    • 8.10.3. Key developments of Physiomics

9. Conclusions

  • 9.1. Current Leading Biosimulation Segments
  • 9.2. Leading Biosimulation Companies
  • 9.3. Leading Regional Markets
  • 9.4. Emerging Biosimulation Market segments
  • 9.5. The Future of the Biosimulation Market?

10. Glossary

  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Figures

  • Figure 2.1: Global Biosimulation Market Segmentation Overview, 2017
  • Figure 3.1: Global Biosimulation Market Segmentation, By Type, 2017
  • Figure 3.2: Biosimulation software Submarkets share Analysis (%) 2016-2027
  • Figure 3.3: Biosimulation Regional Market Share Analysis (%), 2016
  • Figure 3.4: PK/PD Modelling and Simulation Software Market Forecasts, By Geography, Revenue Share Analysis (%), 2016-2027
  • Figure 3.5: Molecular Modelling and Simulation Software Market Forecasts, By Geography, Revenue Share Analysis (%), 2016-2027
  • Figure 3.6: Toxicity Prediction Software Market Forecasts, By Geography, Revenue Share Analysis (%), 2016-2027
  • Figure 3.7: PBPK Modelling and Simulation Software Market Forecasts, By Geography, Revenue Share Analysis (%), 2016-2027
  • Figure 3.8: Trial Design Software Market Forecasts, By Geography, Revenue Share Analysis (%), 2016-2027
  • Figure 3.9: Other Software Market Forecasts By Geography, Revenue Share Analysis (%), 2016-2027
  • Figure 3.10: Biosimulation Services Submarkets, Revenue Share Analysis (%), 2016-2027
  • Figure 3.11: In-House Biosimulation Services Market Forecast, By Geography, Revenue Share Analysis (%), 2016-2027
  • Figure 3.12: External Biosimulation Services Market Share Analysis, By Geography (%), 2016-2027
  • Figure 4.1: Global Biosimulation Market Share Analysis by Application (%), 2017 and 2027
  • Figure 4.2: Biosimulation Applications Market Forecasts ($m), 2016-2027
  • Figure 4.3: Drug Development Market Share Analysis, By Type(%) 2016-2027
  • Figure 4.4: Preclinical Testing Submarket Market Share Analysis, By Geography (%), 2016-2027
  • Figure 4.5: Preclinical Testing Submarket Forecast by Type, (%) 2017
  • Figure 4.6: ADME/Tox Drug Development Market Forecasts, By geography (%) 2016 vs. 2027
  • Figure 4.7: PK/PD Drug Development Market Share Analysis, By Geography (%) 2017
  • Figure 4.8: Clinical Trials Market Share Analysis (%), By Geography, 2017
  • Figure 4.9: Biosimulation Market Forecasts for Drug Discovery, Revenue Share Forecast (%) by Type 2016-2027
  • Figure 4.10: Target Identification and Validation Revenue Share Forecasts (%), By Geography 2017-2027
  • Figure 4.11: Lead Identification and Optimization Revenue Share Forecasts (%), By Geography 2017-2027
  • Figure 4.12: Other Applications Revenue Share Forecasts (%), By Geography 2017-2027
  • Figure 5.1: Biosimulation Market Forecasts, By End Users ($m, AGR%) 2016-2027
  • Figure 5.2: Pharmaceutical and Biotechnology Market Forecasts, By Geography (%) 2017
  • Figure 5.3: Contract research organizations Market Forecasts, By geography ($m, AGR%) 2017
  • Figure 5.4: Academic and Government Research Institutes Market Forecasts, By Geography (%) 2016-2027
  • Figure 5.5: Regulatory Authorities Market Forecasts, By Geography ($m, AGR%) 2017
  • Figure 6.1: Regional Biosimulation Markets Forecasts ($m, AGR%), 2016-2027
  • Figure 6.2: Regional Biosimulation Markets Forecasts ($m, AGR%), 2022-2027
  • Figure 6.3: North American Biosimulation Market Forecasts, by Country (%), 2017
  • Figure 6.4: US Biosimulation Market Forecasts ($m), 2016-2027
  • Figure 6.5: Canada Biosimulation Market Forecasts ($m, AGR%), 2016-2027
  • Figure 6.6: Mexico Biosimulation Market Forecasts ($m, AGR%), 2016-2027
  • Figure 6.7: European Biosimulation Revenue Share (%), 2016
  • Figure 6.8: GermanyBiosimulation Market Forecasts ($m, AGR%), 2016-2027
  • Figure 6.9: France Biosimulation Market Forecasts ($m, AGR%), 2016-2027
  • Figure 6.10: Italy Biosimulation Market Forecasts ($m, AGR%), 2016-2027
  • Figure 6.11: Spain Biosimulation Market Forecasts ($m, AGR%), 2016-2027
  • Figure 6.12: Russia Biosimulation Market Forecasts ($m, AGR%), 2016-2027
  • Figure 6.13: Rest of Europe Biosimulation Market Forecasts ($m, AGR%), 2016-2027
  • Figure 6.14: Asia-Pacific Biosimulation Market Revenue Share (%), 2016
  • Figure 6.15: China Biosimulation Market Forecasts ($m, AGR%), 2016-2027
  • Figure 6.16: India Biosimulation Market Forecasts ($m, AGR%), 2022-2027
  • Figure 6.17: Japan Biosimulation Market Forecasts ($m, AGR%), 2022-2027
  • Figure 6.19: RoW Biosimulation Market Forecasts ($m, AGR%), 2017-2027
  • Figure 6.18: Rest of Asia-Pacific Biosimulation Market Forecasts ($m, AGR%), 2022-2027
  • Figure 7.1: Porter's Five Forces Analysis of the Biosimulation Market, 2075-2027
  • Figure 7.2: Biosimulation Market: Drivers and Restraints, 2017-2027

List of Tables

  • Table 3.1: Biosimulation Submarkets, by Type Forecast ($m, AGR%) 2016-2027
  • Table 3.2: Biosimulation Software Submarkets, Forecast ($m, AGR%) 2026-2027
  • Table 3.3: Biosimulation Software Market Forecasts, By Geography ($m, AGR %), 2016-2027
  • Table 3.4: PK/PD Modelling and Simulation Software Market Forecasts, By Geography ($m, AGR %), 2016-2027
  • Table 3.5: Molecular modelling and simulation software Market Forecasts, By Geography ($m, AGR %), 2016-2027
  • Table 3.6: Toxicity prediction software Market Forecasts, By Geography ($m, AGR %), 2016-2027
  • Table 3.7: PBPK Modelling and Simulation Software Market Forecasts, By Geography ($m, AGR %), 2016-2027
  • Table 3.8: Trial design Software Market Forecasts, By Geography ($m, AGR %), 2016-2027
  • Table 3.9: Other Software Market Forecasts, By Geography 2016-2027
  • Table 3.10: Biosimulation Services Submarkets Forecast ($m, AGR%) 2016-2027
  • Table 3.11: Biosimulation Services Market Forecasts, By Geography ($m, AGR %), 2016-2027
  • Table 3.12: In-House Biosimulation Services Market Forecasts, By Geography ($m, AGR %), 2016-2027
  • Table 3.13: External/Contract Biosimulation Services Market Forecasts, By Geography ($m, AGR %), 2016-2027
  • Table 4.1: Biosimulation Application Market Forecasts ($m, AGR %), 2016-2027
  • Table 4.2: Drug Development Market Forecasts, By Type ($m, AGR%) 2016-2027
  • Table 4.3: Drug Development Market Forecasts, By Geography ($m, AGR (%), CAGR (%)) 2016-2027
  • Table 4.4: Preclinical Testing Submarket Forecast by Type, ($m, AGR (%), CAGR (%))2016-2027
  • Table 4.5: ADME/Tox Drug Development Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
  • Table 4.6: PK/PD Drug Development Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
  • Table 4.7: Clinical Trials Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
  • Table 4.8: Biosimulation Market Forecasts for Drug Discovery, By Type ($m, AGR (%), CAGR (%))2016-2027
  • Table 4.9: Biosimulation Market Forecasts for Drug Discovery, by Geography ($m, AGR (%), CAGR (%)) 2016-2027
  • Table 4.10: Target Identification and Validation Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
  • Table 4.11: Lead Identification and Optimization Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
  • Table 4.12: Other Applications Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
  • Table 5.1: Biosimulation Market Forecasts, By End Users ($m, AGR (%), CAGR (%))2016-2027
  • Table 5.2: Pharmaceutical and Biotechnology Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
  • Table 5.3: Contract Research Organizations Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
  • Table 5.4: Academic and Government Research Institutes Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
  • Table 5.5: Some of the Major Regulatory Authorities Across the Globe
  • Table 5.6: Regulatory Authorities Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
  • Table 5.7: Other End Users Market Forecasts, By Geography ($m, AGR (%), CAGR (%))2016-2027
  • Table 6.1: Leading National Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
  • Table 6.2: Regional Biosimulation Market Forecasts ($m, AGR (%), CAGR (%)), 2016-2027
  • Table 6.3: North American Biosimulation Market Forecasts by Country ($m, AGR (%), CAGR (%)), 2016-2027
  • Table 6.4: US Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
  • Table 6.5: Canadian Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
  • Table 6.6: Mexican Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
  • Table 6.7: European Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
  • Table 6.8: German Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
  • Table 6.9: France Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
  • Table 6.10: Italy Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
  • Table 6.11: Spain Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
  • Table 6.12: Russia Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
  • Table 6.13: Rest of Europe Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
  • Table 6.14: Asia-Pacific Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
  • Table 6.15: Chinese Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
  • Table 6.16: Indian Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
  • Table 6.17: Japanese Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
  • Table 6.18: Rest of Asia-Pacific Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
  • Table 6.19: RoW Biosimulation Market Forecast ($m, AGR (%), CAGR (%)), 2016-2027
  • Table 8.1: Accelrys Key Developments
  • Table 8.2 Certara Biosimulation Products, 2016
  • Table 8.3: Certara Key Developments
  • Table 8.4: Simulation Plus Key Developments
  • Table 8.5: Dassault Systems Key Developments
  • Table 8.6: Schrödinger Key Developments
  • Table 8.7: Advanced Chemistry Development Key Developments
  • Table 8.8: Chemical Computing Group Key Developments
  • Table 8.9: Genedata AG Key Developments
  • Table 8.10: Physiomics AG Key Developments

List of Companies:

  • Accelrys Inc.
  • Advanced Chemistry Development
  • Apriso
  • AstraZeneca
  • BASF
  • Bayer Schering Pharma AG
  • BioSimulation Consulting Inc. (U.S.)
  • BIOVIA
  • BT Group plc.
  • Catalyst Inc.
  • Certara L.P
  • Chemical Computing Group
  • Cognigen Corporation
  • CST - Computer Simulation Technology
  • d3 Medicine
  • Dassualt Systemes
  • Diatech Pharmacogenetics
  • DILIsym Services
  • Du Pont
  • Elsys
  • eMolecules, Inc
  • Engineous Software
  • Enginuity PLM
  • Entelos Holding Corporation
  • Exalead
  • Geensoft
  • Genedata AG
  • Great Lakes Drug Development
  • GSK
  • INOSIM Software GmbH und INOSIM Consulting GmbH
  • Insilico Biotechnology AG
  • Intercim
  • L'Oréal
  • LabLogic Systems Ltd.
  • MatrixOne
  • Netvibes
  • Optivia Biotechnology Inc. (U.S.)
  • Ortems -Unknown
  • P&G
  • Pfizer Inc
  • Physiomics PLC
  • Quintiq
  • Realtime Technology
  • Rhenovia Pharma SAS
  • Rhenovia Pharma SAS (France)
  • Sanofi
  • Schrödinger Inc.
  • Shell
  • Simcyp
  • Simulations Plus Inc.
  • SquareClock
  • Structural Research and Analysis Corporation
  • Synchrogenix
  • Synchrogenix
  • Tripos International
  • Tuscany Design Automation
  • Unilever
  • Veristat, LLC
  • Virtools
  • XenologiQ
  • Discovery Innovations
  • Iconix Biosciences

List of Organizations:

  • Battelle (U.S.)
  • Bill and Melinda Gates Foundation (BMGF) (U.S.)
  • Biotechnology and Biological Sciences Research Council (BBSRC) (UK)
  • California Biomedical Research Association
  • Center for Food Safety and Applied Nutrition (CFSAN)
  • Center for Information and Study on Clinical Research Participation (CISCRP) (U.S.)
  • Central Drug Standard Control Organization (CDSCO)
  • Danish Medicines Agency
  • European Medicines Agency
  • Food and Drug Administration (FDA)
  • Hamner Institutes for Health Sciences
  • Health Canada
  • Kyushu University (Japan)
  • Levada Center
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Medsafe - Medicines and Medical Devices Safety Authority
  • Ministry of Health, Labor, and Welfare (MHLW)
  • National Center for Chronic Disease Prevention and Health Promotion
  • National Health Service (UK)
  • National Institutes of Health (NIH)
  • Organization for Economic Co-operation and Development (OECD)
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Research Council of Norway
  • Roszdravnadzor
  • Sistema Sanitario Nazionale (Italy)
  • South Africa Medical Research Council (MRC)
  • Texas A&M University (U.S.)
  • The National University of Singapore (Singapore)
  • Therapeutic Goods Administration (TGA)
  • TU Dortmund University
  • University of California
  • University of Cape Town (UCT)
  • World Health Organization (WHO)
Back to Top